397 related articles for article (PubMed ID: 15041104)
1. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.
Haab F; Stewart L; Dwyer P
Eur Urol; 2004 Apr; 45(4):420-9; discussion 429. PubMed ID: 15041104
[TBL] [Abstract][Full Text] [Related]
2. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist.
Steers W; Corcos J; Foote J; Kralidis G
BJU Int; 2005 Mar; 95(4):580-6. PubMed ID: 15705084
[TBL] [Abstract][Full Text] [Related]
3. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder.
Chapple C; Steers W; Norton P; Millard R; Kralidis G; Glavind K; Abrams P
BJU Int; 2005 May; 95(7):993-1001. PubMed ID: 15839920
[TBL] [Abstract][Full Text] [Related]
4. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist.
Foote J; Glavind K; Kralidis G; Wyndaele JJ
Eur Urol; 2005 Sep; 48(3):471-7. PubMed ID: 15990219
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
Wagg A; Wyndaele JJ; Sieber P
Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB.
Zinner N; Susset J; Gittelman M; Arguinzoniz M; Rekeda L; Haab F
Int J Clin Pract; 2006 Jan; 60(1):119-26. PubMed ID: 16409440
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study.
Haab F; Corcos J; Siami P; Glavind K; Dwyer P; Steel M; Kawakami F; Lheritier K; Steers WD
BJU Int; 2006 Nov; 98(5):1025-32. PubMed ID: 16879437
[TBL] [Abstract][Full Text] [Related]
8. Increased warning time with darifenacin: a new concept in the management of urinary urgency.
Cardozo L; Dixon A
J Urol; 2005 Apr; 173(4):1214-8. PubMed ID: 15758755
[TBL] [Abstract][Full Text] [Related]
9. Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial.
Chapple C; DuBeau C; Ebinger U; Rekeda L; Viegas A
Curr Med Res Opin; 2007 Oct; 23(10):2347-58. PubMed ID: 17706004
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of health-related quality of life outcomes with darifenacin.
Abrams P; Kelleher C; Huels J; Quebe-Fehling E; Omar MA; Steel M
BJU Int; 2008 Jul; 102(2):208-13. PubMed ID: 18325056
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z
BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
[TBL] [Abstract][Full Text] [Related]
12. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia.
Kaplan SA; Roehrborn CG; Dmochowski R; Rovner ES; Wang JT; Guan Z
Urology; 2006 Aug; 68(2):328-32. PubMed ID: 16904446
[TBL] [Abstract][Full Text] [Related]
13. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
Robinson D; Cardozo L; Terpstra G; Bolodeoku J;
BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
[TBL] [Abstract][Full Text] [Related]
14. Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study.
Hill S; Khullar V; Wyndaele JJ; Lheritier K;
Int Urogynecol J Pelvic Floor Dysfunct; 2006 May; 17(3):239-47. PubMed ID: 15999217
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers.
Kay GG; Wesnes KA
BJU Int; 2005 Nov; 96(7):1055-62. PubMed ID: 16225528
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
[TBL] [Abstract][Full Text] [Related]
17. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome.
Haab F; Cardozo L; Chapple C; Ridder AM;
Eur Urol; 2005 Mar; 47(3):376-84. PubMed ID: 15716204
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M;
BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome.
Nitti VW; Dmochowski R; Sand PK; Forst HT; Haag-Molkenteller C; Massow U; Wang J; Brodsky M; Bavendam T
J Urol; 2007 Dec; 178(6):2488-94. PubMed ID: 17937959
[TBL] [Abstract][Full Text] [Related]
20. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial.
Karram MM; Toglia MR; Serels SR; Andoh M; Fakhoury A; Forero-Schwanhaeuser S
Urology; 2009 Jan; 73(1):14-8. PubMed ID: 18995887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
